The Solution Provider for 
Drug Discovery in Oncology

ProQinase is a leading contract research company for cancer drug discovery. The company has a long-standing scientific experience in cancer research with a focus on protein kinases and tumor angiogenesis.

Currently 275 in-house produced catalytically active protein kinases, 11 lipid kinases and 14 kinase substrates are offered for sale. Furthermore, 396 protein kinases and 13 lipid kinases are available for biochemical kinase assay services (HTS, selectivity profiling and IC50 determination).

Hits derived from biochemical kinase assays can be further characterized at ProQinase in cell-based, target-specific phosphorylation assays and in various functional cell-based assays like migration assays, proliferation assays, soft agar assays, and angiogenesis assays.

ProQinase’s portfolio of preclinical services is completed by in vivo testing services including subcutaneous tumor models (xenograft tumor models), orthotopic tumor models with in vivo and ex vivo bioluminescence analysis and a unique in vivo angiogenesis assay.

In addition, ProQinase provides custom-tailored solutions of preclinical services as support for cancer drug discovery projects.

 
cancer research, contract research, preclinical services, cancer drug discovery
Imprint | Copyright 2002-2014 ProQinase GmbH. All rights reserved.
Christmas holiday season:

Dear Visitor,
Thank you for your interest in our products & services. We would like to inform you that during the Christmas / New Year period ProQinase GmbH will be closed from 24th of December to the 4th of January 2015. We will reply to your e-mails and calls as soon as possible in the first week of January 2015. Shipment of our products will start again on January the 7th, 2015.

We are looking forward to getting in touch with you in 2015.
Seasons's greetings and best wishes for the New Year.
Your ProQinase-Team

Meet ProQinase at
SLAS2015, February 7–11, 2015 at booth #211, Walter E. Washington Convention Center, Washington, DC, USA